title: Higher risk of venous thrombosis during early use of oral contraceptives in women with inherited clotting defects.
abstract: BACKGROUND
  Results of recent studies show that the risk for venous thrombosis is highest during initial oral contraceptive use. This suggests a subgroup of females who are at immediate risk of thrombosis when exposed to oral contraceptives.
  
  
  OBJECTIVE
  To determine whether women with inherited clotting defects who use oral contraceptives develop venous thrombosis at an earlier stage than do those without inherited clotting defects.
  
  
  METHODS
  Analysis of the data from the Leiden Thrombophilia Study, a population-based case-control study with data on duration of oral contraceptive use and recently detected genetic coagulation disorders. Patients had a first episode of objectively proven deep vein thrombosis. Patients and controls were considered thrombophilic when they had protein C deficiency, protein S deficiency, antithrombin deficiency, factor V Leiden mutation, or prothrombin 20210 A mutation.
  
  
  RESULTS
  Risk of developing deep vein thrombosis was greatest in the first 6 months and the first year of oral contraceptive use. Compared with prolonged use, the risk of developing deep vein thrombosis was 3-fold higher in the first 6 months of use (95% confidence interval [CI], 0.6-14.8) and 2-fold higher in the first year of use (95% CI, 0.6-6.1). Patients who developed venous thrombosis in the early periods of use were more often thrombophilic. Among women with thrombophilia, the risk of developing deep vein thrombosis during the first 6 months of oral contraceptive use (compared with prolonged use) was increased 19-fold (95% CI, 1.9-175.7), and in the first year of use, it was increased 11-fold (95% CI, 2.1-57.3).
  
  
  CONCLUSIONS
  Women with inherited clotting defects who use oral contraceptives develop venous thrombosis not only more often but also sooner than do those without inherited clotting defects. Venous thrombosis in the first period of oral contraceptive use might indicate the presence of an inherited clotting defect.
authors.affiliation: Department of Obstetrics, Gynecology, and Reproductive Medicine, University Hospital Leiden, The Netherlands.
authors.forename: K W
authors.initials: KW
authors.lastname: Bloemenkamp
authors.forename: F R
authors.initials: FR
authors.lastname: Rosendaal
authors.forename: F M
authors.initials: FM
authors.lastname: Helmerhorst
authors.forename: J P
authors.initials: JP
authors.lastname: Vandenbroucke
mesh_terms: D000293:Adolescent; D000328:Adult; D001778:Blood Coagulation Disorders / Q000235:genetics*; D016022:Case-Control Studies; D003276:Contraceptives, Oral / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008875:Middle Aged; D012306:Risk; D012307:Risk Factors; D013997:Time Factors; D020246:Venous Thrombosis / Q000139:chemically induced* / Q000235:genetics*
chemical_list: D003276:Contraceptives, Oral